Results 261 to 270 of about 756,046 (308)
Some of the next articles are maybe not open access.
Dose-response relationships with antihypertensive drugs
Pharmacology & Therapeutics, 1992A variety of antihypertensive drugs have been introduced into clinical practice at excessively high dose. Examples include most thiazide diuretics, propranolol, oxprenolol, atenolol, methyldopa, hydralazine and captopril. These very high doses have usually resulted from studies in which doses have been increased at regular intervals until the desired ...
openaire +2 more sources
Pharmacogenetics and Genetic Factors in Drug Dose-Response Relationships
2023Abstract Pharmacogenetics and pharmacogenomics are related areas of research that aim to determine the relationship between genotypic variation, including changes in gene expression, and variations in drug response seen across patient groups. Understanding the genetic bases of variability in drug response due to altered pharmacokinetics (
openaire +1 more source
The multiple propensity score for analysis of dose–response relationships in drug safety studies
Pharmacoepidemiology and Drug Safety, 2001AbstractIn order to detect adverse drug reactions, large observational drug safety studies are necessary as randomized clinical trials rarely have enough power. However, in order to obtain reliable results the issue of confounding, especially confounding by indication, should be addressed.
Wang, Jixian +3 more
openaire +3 more sources
AAPS PharmSciTech, 2023
The objective of this study is to investigate the dose-response relationship between various concentrations of permeation enhancers (PEs) and their ability to enhance drug release from a polymer matrix, utilizing an innovative parameter known as release enhancement efficiency (K). Additionally, the molecular mechanism underlying dynamic enhancement was
Jiuheng Ruan +3 more
openaire +2 more sources
The objective of this study is to investigate the dose-response relationship between various concentrations of permeation enhancers (PEs) and their ability to enhance drug release from a polymer matrix, utilizing an innovative parameter known as release enhancement efficiency (K). Additionally, the molecular mechanism underlying dynamic enhancement was
Jiuheng Ruan +3 more
openaire +2 more sources
Journal of Biopharmaceutical Statistics, 2015
Clinical trials often involve comparing 2-4 doses or regimens of an experimental therapy with a control treatment. These studies might occur early in a drug development process, where the aim might be to demonstrate a basic level of proof (the so-called proof of concept (PoC) studies), at a later stage, to help establish a dose or doses that should be ...
David, Ohlssen, Amy, Racine
openaire +2 more sources
Clinical trials often involve comparing 2-4 doses or regimens of an experimental therapy with a control treatment. These studies might occur early in a drug development process, where the aim might be to demonstrate a basic level of proof (the so-called proof of concept (PoC) studies), at a later stage, to help establish a dose or doses that should be ...
David, Ohlssen, Amy, Racine
openaire +2 more sources
Cellular and Molecular Bioengineering, 2021
Ischemic stroke treatment has advanced in the last two decades and intravenous thrombolysis is now considered the standard of care for selected patients. Recanalization can also be achieved by mechanical endovascular treatment for patients with large vessel occlusions.
Qin, Zhen +4 more
openaire +3 more sources
Ischemic stroke treatment has advanced in the last two decades and intravenous thrombolysis is now considered the standard of care for selected patients. Recanalization can also be achieved by mechanical endovascular treatment for patients with large vessel occlusions.
Qin, Zhen +4 more
openaire +3 more sources
Drug Action: Target Tissue, Dose-Response Relationships, and Receptors
1972In the complex processes of drug action three main phases can be distinguished (Fig. 1): the pharmaceutical phase, the pharmacokinetic phase and the pharmacodynamic phase. They form a suitable frame for the discussion of the chemical basis of drug action.
E. J. Ariëns, A. M. Simonis
openaire +1 more source
Journal of Psychoactive Drugs, 1995
This study examined the impact of treatment intensity on cocaine use. Seventy-seven cocaine-using methadone patients were enrolled in a six-month, structured, manual-driven, cognitive-behavioral treatment program. Sessions consisted of five individual and/or group sessions per week.
A, Rosenblum +6 more
openaire +2 more sources
This study examined the impact of treatment intensity on cocaine use. Seventy-seven cocaine-using methadone patients were enrolled in a six-month, structured, manual-driven, cognitive-behavioral treatment program. Sessions consisted of five individual and/or group sessions per week.
A, Rosenblum +6 more
openaire +2 more sources
The American Journal of Medicine, 1989
Based on pooled data from three randomized placebo-controlled dose-finding studies in a total of 489 patients, the dose-response relationship for efficacy and adverse events was estimated, using the Michaelis-Menten equation: Effect = maximal effect multiplied by dose/constant plus dose. Three conclusions were derived from the pooled data: (1) A marked
K, Simonsen, C D, Sundstedt
openaire +2 more sources
Based on pooled data from three randomized placebo-controlled dose-finding studies in a total of 489 patients, the dose-response relationship for efficacy and adverse events was estimated, using the Michaelis-Menten equation: Effect = maximal effect multiplied by dose/constant plus dose. Three conclusions were derived from the pooled data: (1) A marked
K, Simonsen, C D, Sundstedt
openaire +2 more sources
Drug Metabolism and Disposition, 1991
A monoclonal antibody was used to study the dose-response relationship for antibody-mediated redistribution of tricyclic antidepressants (TCA) in rats. The antibody (anti-TCA) was an IgG1 with Ka = 3.0 x 10(8) M-1 for desipramine (DMI) and 2.2 x 10(8) M-1 for imipramine (IMI).
P R, Pentel +6 more
openaire +2 more sources
A monoclonal antibody was used to study the dose-response relationship for antibody-mediated redistribution of tricyclic antidepressants (TCA) in rats. The antibody (anti-TCA) was an IgG1 with Ka = 3.0 x 10(8) M-1 for desipramine (DMI) and 2.2 x 10(8) M-1 for imipramine (IMI).
P R, Pentel +6 more
openaire +2 more sources